Peculiarities of diagnostication and treatment of cases of headache associated with migraine attacks
ARTICLE PDF (Русский)

Keywords

migraine, chronic migraine, clinical presentation, diagnostics, treatment.

How to Cite

Svyrydova, N. (2015). Peculiarities of diagnostication and treatment of cases of headache associated with migraine attacks. East European Journal of Neurology, (1(1), 8-12. https://doi.org/10.33444/2411-5797.2015.1(1).8-12

Abstract

Migraine is a frequent neurological disorder that is recorded in 12.6% of the population (6% of men, 18% women). According to the WHO, migraine is on the list of 20 most debilitating diseases in the world. The article outlines the classification, clinical and neurological characteristics and diagnostic criteria of migraine types. The article describes the modifiable risk factors and differential diagnosis of chronic migraine. The article provides the treatment principles of migraine according to the level of evidence of major groups of antimigraine medications and their possible side effects and complications.

https://doi.org/10.33444/2411-5797.2015.1(1).8-12
ARTICLE PDF (Русский)

References

[1] Marmura M., Silberstein S., Schwedt T. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies//Headache. 2015 Jan;55(1):3-20.
[2] Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:1587-92.
[3] Lainez MJ, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007;14:269-75.
[4] Hall G, Brown M, Mo J, MacRae KD. Triptans in migraine:the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563-8.
[5] Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:1587-92.
[6] Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:1587-92.
[7] Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother 2007;8:3029-33.
[8] Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003;17:653-67.
[9] Dahlof C, Cady R, Poole AC. Speed of onset and efficacy of sumatriptan fast-disintegrating/rapid release tablets:results of two replicate randomised, placebo-controlled studies. Headache Care 2004;1:277-80.
[10] Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose- finding study. Cephalalgia 1984;4:85-90.
[11] Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychchiatry 1973;36:684-90.
[12] Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-9.
[13] Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486-9.
[14] Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine: pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:825-30.
[15] Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992;32:101-4.
[16] Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998;18:283-6.
[17] dAmato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a doubleblind trial. Headache 1999;39:716-9.
[18] Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994;34:497-502.
[19] Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45:144-52.
[20] Adelman LC, Adelman JU, von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000;40:572-80.
[21] Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004;107:44-8.